This Day That Year: Unum Therapeutics

(RTTNews) - Shares of Unum Therapeutics Inc. (UMRX) are down nearly 75% from their all-time high of $17.66 recorded on August 7, 2018.

It was on this day last year, i.e. on March 29, 2018, that Unum debuted on the Nasdaq Global Select Market by setting a public offering at $12 per share.

Unum is a clinical-stage biopharmaceutical company developing novel immunotherapy products designed to harness the power of a patient's immune system to cure cancer.

The Company's product candidates are composed of antibody-coupled T cell receptor (ACTR) cells co-administered with approved and commercially available antibodies or antibodies in preclinical or clinical development to target different tumor types. The pipeline includes 4 clinical-stage programs that are based on the ACTR platform and 1 pre-clinical program.

The lead product candidate is ACTR707 used in combination with Rituximab in adult patients with relapsed/ refractory (r/r) non-Hodgkin lymphoma, under a phase I trial, dubbed ATTCK-20-03. The Company expects to define the recommended phase II dose (RP2D) of ACTR707 and initiate a cohort expansion at the RP2D in the second half of 2019.

Next up in the pipeline is ACTR087, used in combination with Rituximab in adult patients with r/r non-Hodgkin lymphoma, under a phase I trial, dubbed ATTCK-20-02. The updated data from all patients enrolled in the ATTCK-20-2 trial are expected at the end of 2019.

The Company's third clinical stage program is ACTR087 in combination with SEA-BCMA in adult patients with r/r multiple myeloma in a Phase I multi-center trial, dubbed ATTCK-17-01. Additional data from this study are expected in the second half of 2019. This is the first program resulting from Unum's strategic collaboration with Seattle Genetics Inc. (SGEN) that was signed in June 2015.

A phase I multi-center trial evaluating ACTR707 in combination with Trastuzumab as a potential treatment for advanced HER2+ solid tumor cancers, dubbed ATTCK-34-01, is underway. Initial clinical data from this study is expected at the end of 2019.

The Company's pre-clinical program is BOXR1030, which targets GPC3, an oncofetal antigen expressed in a variety of tumors including certain liver and lung cancers.

Since inception in March 2014, Unum has incurred net losses in every year, and as of December 31, 2018, had an accumulated deficit of $92.1 million. The Company ended the year 2018 with cash, cash equivalents, and marketable securities of $78.6 million, which is expected to be sufficient till early 2021.

Given the fact that the Company is expected to report data from all of its ongoing trials in 2019, it may be worth keeping an eye on this stock.

UMRX has thus far hit a low of $3.59 and a high of $17.66. The stock closed Thursday's trading at $4.41, up 8.62%.